For the Inventor, By the Inventor

Enter assignee name

Astellas Pharma Gmbh

USPTO Granted Patents = 417

CIPO Patents = 55

EPO Patents = 202

Trademarks = 55

Forward Citations = 1,713

Loading Chart...

Loading Chart...

967 inventors (with patents filed for the assignee):

Hiroyuki Moritomo (21 out of 28 patents)

Ugur Sahin (19 out of 182 patents)

Ryushi Seo (16 out of 16 patents)

4. Yuji Koga (15 out of 16 patents)

5. Hiroyuki Kaizawa (15 out of 21 patents)

6. Keizo Sugasawa (14 out of 15 patents)

7. Ozlem Tureci (13 out of 53 patents)

8. Fukushi Hirayama (13 out of 17 patents)

9. Takashi Sugane (12 out of 12 patents)

10. Akio Kamikawa (12 out of 13 patents)

11. Susumu Yamaki (11 out of 15 patents)

12. Jun Takasaki (11 out of 14 patents)

13. Takashi Furutani (11 out of 16 patents)

14. Kazuhiro Sako (11 out of 17 patents)

15. Rita Mitnacht-Kraus (10 out of 16 patents)

Core Competencies:

Enzalutamide Formulations

Antibody-Drug Complex

G12D Mutant KRAS Degradation

Bispecific Antibodies

Thrombin Hemostatic Sheet

Cancer Prognosis Prediction

Modified Release Pharmaceutical Composition

Claudin 18.2 Antibodies

Cell Penetrating Peptides

Oncolytic Vaccinia Virus Therapy

Regulatory T Cell Production

Transcriptional Regulatory Polypeptides

417 patents: Sort by Forward Citations

1. 12502357 - Formulations of enzalutamide (2025-12-23),

2. 12447128 - Formulations of enzalutamide (2025-10-21),

3. 12390536 - Antibody-drug complex containing toll-like receptor 7/8 dual agonist compound (2025-08-19),

4. 12384794 - Quinazoline compound for inducing degradation of G12D mutant KRAS protein (2025-08-12),

5. 12304951 - Anti-TSPAN8/anti-CD3 bispecific antibody and anti-TSPAN8 antibody (2025-05-20),

6. 12251491 - Thrombin-carrying hemostatic sheet (2025-03-18),

7. 12227586 - Anti-CLDN4/anti-CD137 bispecific antibody (2025-02-18),

8. 12227517 - Pyridazinyl-thiazolecarboxamide compound (2025-02-18),

9. 12209134 - Anti-human Fn14 antibody (2025-01-28),

10. 12202908 - Complex having anti-human MUC1 antibody Fab fragment, peptide linker and/or ligand (2025-01-21),

11. 12188097 - Methods and compositions for prediction of therapeutic efficacy of cancer treatments and cancer prognosis (2025-01-07),

12. 12178814 - Pharmaceutical composition (2024-12-31),

13. 12161628 - Combination therapy (2024-12-10),

14. 12097189 - Pharmaceutical composition for modified release (2024-09-24),

15. 12077519 - Heteroaryl carboxamide compound (2024-09-03),

Astellas Pharma GmbH is a pharmaceutical company that specializes in the research, development, and manufacturing of innovative drugs and medical solutions. With a focus on improving the health of people around the world, Astellas Pharma GmbH strives to create breakthrough therapies that address unmet medical needs in various therapeutic areas. By combining cutting-edge technology, scientific expertise, and a patient-centric approach, they are dedicated to helping patients and healthcare professionals achieve better outcomes and improve the quality of life.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

417 Patents

#188 in

#416 in Germany

#2,195 in the World

Astellas Pharma Gmbh

Forward Citations = 1,713

967 inventors:

Hiroyuki Moritomo (21 out of 28 patents)

Ugur Sahin (19 out of 182 patents)

Ryushi Seo (16 out of 16 patents)

4. Yuji Koga (15 out of 16 patents)

5. Hiroyuki Kaizawa (15 out of 21 patents)

Please report any incorrect information to support@idiyas.com

Loading…